Impact of VEGF-dependent tumour micro-environment on EDB fibronectin expression by subcutaneous human tumour xenografts in nude mice

Journal of Pathology

Volumn 219, Issue 4, 2009, Pages 455-462

  Coltrini, Daniela ^a   Ronca, Roberto ^a   Belleri, Mirella ^a   Zardi, Luciano ^b   Indraccolo, Stefano ^c   Scarlato, Valentina ^d   Giavazzi, Raffaella ^d   Presta, Marco ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Angiogenesis; EDB FN; Fibronectin; Gene expression; Immunohistochemistry; Neoplasia; Nude mice; Quantitative RT PCR; Tumour micro environment; Tumour xenograft; Vascular targeting

Indexed keywords

BEVACIZUMAB; COMPLEMENTARY DNA; EXTRA DOMAIN B CONTAINING FIBRONECTIN; FIBROBLAST GROWTH FACTOR 2; FIBRONECTIN; MONOCLONAL ANTIBODY DC101; TETRACYCLINE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GRAFT; CANCER MODEL; CELL STRAIN CAKI 1; CELL STRAIN KYSE 30; CONTROLLED STUDY; DOWN REGULATION; ENDOMETRIUM CARCINOMA; ESOPHAGUS CANCER; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MICROENVIRONMENT; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION; UPREGULATION; XENOGRAFT;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ENDOMETRIAL NEOPLASMS; FEMALE; FIBROBLAST GROWTH FACTOR 2; FIBRONECTINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MICE; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 72249097684     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2626     Document Type: Article

References (27)

1. Ruoslahti E. Fibronectin and its receptors. Annu Rev Biochem 1988;57:375-413.
2. Schwarzbauer JE, Tamkun JW, Lemischka IR, Hynes RO. Three different fibronectin mRNAs arise by alternative splicing within the coding region. Cell 1983;35:421-431.
3. Zardi L, Carnemolla B, Siri A, Petersen TE, Paolella G, Sebastio G, et al. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J 1987;6:2337-2342.
4. Castellani P, Viale G, Dorcaratto A, Nicolo G, Kaczmarek J, Querze G, et al. The fibronectin isoform containing the EDB oncofetal domain: a marker of angiogenesis. Int J Cancer 1994;59:612-618. (Pubitemid 24358583)
5. Fukuda T, Yoshida N, Kataoka Y, Manabe R, Mizuno-Horikawa Y, Sato M, et al. Mice lacking the EDB segment of fibronectin develop normally but exhibit reduced cell growth and fibronectin matrix assembly in vitro. Cancer Res 2002;62:5603-5610.
6. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1995;1:27-31.
7. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611. (Pubitemid 39099316)
8. Brower V. Antiangiogenesis research is booming, as questions and studies proliferate. J Natl Cancer Inst 2009;101:780-781.
9. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10:415-427. (Pubitemid 38173977)
10. Neri D, Bicknell R. Tumour vascular targeting. Nature Rev Cancer 2005;5:436-446.
11. Schliemann C, Neri D. Antibody-based targeting of the tumor vasculature. Biochim Biophys Acta 2007;1776:175-192.
12. Kaspar M, Zardi L, Neri D. Fibronectin as target for tumor therapy. Int J Cancer 2006;118:1331-1339.
13. Pini A, Viti F, Santucci A, Carnemolla B, Zardi L, Neri P, et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 1998;273:21769-21776. (Pubitemid 28405353)
14. Ebbinghaus C, Scheuermann J, Neri D, Elia G. Diagnostic and therapeutic applications of recombinant antibodies: targeting the extra-domain B of fibronectin, a marker of tumor angiogenesis. Curr Pharm Des 2004;10:1537-1549. (Pubitemid 38559765)
15. Sauer S, Erba PA, Petrini M, Menrad A, Giovannoni L, Grana C, et al. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 2009;113:2265-2274.
16. Giavazzi R, Giuliani R, Coltrini D, Bani MR, Ferri C, Sennino B, et al. Modulation of tumor angiogenesis by conditional expression of fibroblast growth factor-2 affects early but not established tumors. Cancer Res 2001;61:309-317. (Pubitemid 32095732)
17. Coltrini D, Gualandris A, Nelli EE, Parolini S, Molinari-Tosatti MP, Quarto N, et al. Growth advantage and vascularization induced by basic fibroblast growth factor overexpression in endometrial HEC-1-B cells: an export-dependent mechanism of action. Cancer Res 1995;55:4729-4738.
18. Giavazzi R, Sennino B, Coltrini D, Garofalo A, Dossi R, Ronca R, et al. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis. Am J Pathol 2003;162:1913-1926. (Pubitemid 36613049)
19. Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999;59:5209-5218. (Pubitemid 29503984)
20. Carnemolla B, Balza E, Siri A, Zardi L, Nicotra MR, Bigotti A, et al. A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J Cell Biol 1989;108:1139-1148. (Pubitemid 19083757)
21. Carnemolla B, Leprini A, Allemanni G, Saginati M, Zardi L. The inclusion of the type III repeat ED-B in the fibronectin molecule generates conformational modifications that unmask a cryptic sequence. J Biol Chem 1992;267:24689-24692.
22. Midulla M, Verma R, Pignatelli M, Ritter MA, Courtenay- Luck NS, George AJ. Source of oncofetal ED-B-containing fibronectin: implications of production by both tumor and endothelial cells. Cancer Res 2000;60:164-169. (Pubitemid 30058747)
23. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nature Med 2003;9:677-684. (Pubitemid 36749216)
24. Srebrow A, Blaustein M, Kornblihtt AR. Regulation of fibronectin alternative splicing by a basement membrane-like extracellular matrix. FEBS Lett 2002;514:285-289. (Pubitemid 34273955)
25. Kriegsmann J, Berndt A, Hansen T, Borsi L, Zardi L, Brauer R, et al. Expression of fibronectin splice variants and oncofetal glycosylated fibronectin in the synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Rheumatol Int 2004;24:25-33. (Pubitemid 38168110)
26. Borsi L, Castellani P, Risso AM, Leprini A, Zardi L. Transforming growth factor-beta regulates the splicing pattern of fibronectin messenger RNA precursor. FEBS Lett 1990;261:175-178. (Pubitemid 20064800)
27. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996;2:1843-1849. (Pubitemid 26384151)